Much like previous efforts towards functionalizing high-frequency aberrations for clinical translation (that is, targeted therapeutics for activating mutations in EGFR, BRAF and others), identifying rare driver mutations and their mode-of-action has the potential to reveal new tumour vulnerabilities, particularly when found to activate pathways with existing therapies. Here, BRAF is linked to neoplasm.